Publication of List of Manufacturers Suspended Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth of Australia's Parliament, was designed to regulate the supply of therapeutic goods in Australia, ensuring they are of acceptable quality and safety. One of its key objectives is to maintain a list of manufacturers and their licences, which can be suspended if certain conditions are not met. This Act addresses the problem of ensuring that only those who comply with stringent quality and safety standards are allowed to manufacture therapeutic goods. The Therapeutic Goods Administration, under the Department of Health, is responsible for overseeing compliance with the Act. In accordance with section 41 of the Therapeutic Goods Act 1989, the Therapeutic Goods Administration has the authority to suspend the licences of manufacturers who request such action, ensuring that any potential risks to public health are mitigated. The recent suspension of licences for Veolia Environmental Services (Australia) Pty Ltd and the Royal Adelaide Hospital Radiopharmacy, from 28 June 2019 to 28 June 2021 and 1 July 2021 respectively, exemplifies the Administration's commitment to upholding the Act's policy objectives of protecting public health by controlling the quality and safety of therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, ensuring their safety, quality, and efficacy. Under this Act, the Therapeutic Goods Administration (TGA) has the authority to suspend the licences of entities involved in the manufacture of therapeutic goods. The publication in question pertains to the suspension of manufacturing licences for specific entities, illustrating the TGA's regulatory oversight and enforcement capabilities. The Act applies to entities such as VEOLIA ENVIRONMENTAL SERVICES (AUSTRALIA) PTY LTD and ROYAL ADELAIDE HOSPITAL RADIOPHARMACY, both of which are subject to the TGA's jurisdiction due to their involvement in the manufacture of therapeutic goods. The suspension of their licences, which was requested by the manufacturers themselves, serves to highlight the TGA's commitment to maintaining high standards in the therapeutic goods industry. The geographic reach of this legislation is national, as it is administered by the Commonwealth of Australia through the Department of Health. While the Act itself provides the primary framework for regulation, the scope and application of specific provisions can be extended or modified through subordinate instruments, ensuring flexibility and responsiveness to emerging issues in the therapeutic goods sector.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") contains various provisions relating to the regulation of therapeutic goods in Australia, including the suspension of manufacturing licenses. Section 41(1)(d) of the Act allows the Secretary to suspend a license to manufacture therapeutic goods under certain circumstances. This section is particularly pertinent to the suspension of the licence held by VEOLIA ENVIRONMENTAL SERVICES (AUSTRALIA) PTY LTD (Licence No. 83579) and ROYAL ADELAIDE HOSPITAL RADIOPHARMACY (Licence No. MI-12112004-LI-000163-1). The suspension of these licenses was made effective from 28 June 2019 to 28 June 2021 for VEOLIA ENVIRONMENTAL SERVICES (AUSTRALIA) PTY LTD, and from 28 June 2019 to 1 July 2021 for ROYAL ADELAIDE HOSPITAL RADIOPHARMACY. These suspensions were carried out at the request of the respective manufacturers. Under the Act, the obligations of the entities whose licenses are suspended include ceasing all activities related to the manufacture of therapeutic goods that were covered by the licenses. This means that VEOLIA ENVIRONMENTAL SERVICES (AUSTRALIA) PTY LTD and ROYAL ADELAIDE HOSPITAL RADIOPHARMACY are not permitted to manufacture any therapeutic goods during the suspension period unless specific exemptions are granted by the Secretary. Additionally, these entities must ensure that any ongoing manufacturing processes are halted and that any products already in production are not released until the suspension period has ended and the license has been reinstated or replaced with a new one. The suspended entities are also required to comply with any further instructions or conditions imposed by the Secretary during the suspension period. The Therapeutic Goods Act 1989 outlines potential offences and penalties for breaches of its provisions, including the unauthorized manufacture of therapeutic goods during a suspension period. Any entity that fails to comply with the suspension of their manufacturing license could face both civil and criminal penalties. Civil penalties may include fines up to a significant amount, as stipulated by the Act, and in severe cases, criminal penalties can be imposed. The maximum penalties for offences under the Act can include substantial fines and imprisonment, reflecting the serious nature of ensuring the safety and quality of therapeutic goods in Australia. It is crucial for the suspended entities to adhere strictly to the terms of their suspension to avoid these serious consequences.